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ABSTRACT
Cannabinoid receptors (CB) are expressed throughout human skin epithelium. CB1
activation inhibits human hair growth and decreases proliferation of epidermal ker-
atinocytes. Since psoriasis is a chronic hyperproliferative, inflammatory skin disease,
it is conceivable that the therapeutic modulation of CB signaling, which can inhibit
both proliferation and inflammation, could win a place in future psoriasis manage-
ment. Given that psoriasis is characterized by up-regulation of keratins K6 and K16,
we have investigated whether CB1 stimulation modulates their expression in human
epidermis. Treatment of organ-cultured human skin with the CB1-specific agonist,
arachidonoyl-chloro-ethanolamide (ACEA), decreased K6 and K16 staining intensity
in situ. At the gene and protein levels, ACEA also decreased K6 expression of cultured
HaCaT keratinocytes, which show some similarities to psoriatic keratinocytes. These
effects were partly antagonized by the CB1-specific antagonist, AM251. While CB1-
mediated signaling also significantly inhibited human epidermal keratinocyte pro-
liferation in situ, as shown by K6/Ki-67-double immunofluorescence, the inhibitory
effect of ACEA on K6 expression in situ was independent of its anti-proliferative
effect. Given recent appreciation of the role of K6 as a functionally important protein
that regulates epithelial wound healing in mice, it is conceivable that the novel CB1-
mediated regulation of keratin 6/16 revealed here also is relevant to wound healing.
Taken together, our results suggest that cannabinoids and their receptors constitute a
novel, clinically relevant control element of human K6 and K16 expression.
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INTRODUCTION
Endocannabinoids as well as exocannabinoids (such as the active components of cannabis)
control the function of various types of cells via cannabinoid receptor (CB)-dependent
or independent manner (Kupczyk, Reich & Szepietowski, 2009). The endocannabinoid
system (ECS) consists of these CBs, their endogenous ligands (i.e. endocannabinoids,
such as anandamide [AEA] and 2-arachidonoylglycerol), and enzymes responsible for
endocannabinoid synthesis and degradation (Biro et al., 2009). In human skin, many
different types of cells are now known to express functional CBs (Biro et al., 2009; Czifra et
al., 2012; Pucci et al., 2012; Roelandt et al., 2012; Stander et al., 2005; Sugawara et al., 2012;
Telek et al., 2007; Toth et al., 2011). The ECS is increasingly appreciated as an important
regulator of skin function in health and disease. For example, the ECS has become
implicated in pain (Khasabova et al., 2012; Walker & Hohmann, 2005) and itch control
(Stander, Reinhardt & Luger, 2006), and the modulation of inflammation (Klein, 2005) and
allergy (Karsak et al., 2007). In addition, CB1 signaling is important in mast cell activation
and intracutaneous mast cell maturation from resident progenitors (Sugawara et al., 2012).
Furthermore, it regulates fibrosis (Akhmetshina et al., 2009), sebocyte differentiation
(Dobrosi et al., 2008) and eccrine epithelial biology (Czifra et al., 2012). Nevertheless,
the functions of CB-mediated signaling in human keratinocytes (KCs) in situ are as yet
poorly understood.
We have previously shown that outer root sheath KCs of human hair follicles (HFs)
express CB1. CB1 stimulation by the endocannabinoid, AEA, markedly inhibited human
HF growth by inhibiting hair matrix KC proliferation and inducing apoptosis, thus leading
to premature HF involution (catagen development). This was reversed by the CB1-specific
antagonist, AM251 (Telek et al., 2007). Similarly, human epidermal KC express CBs, and
their differentiation is regulated via CB1 (Maccarrone et al., 2003; Paradisi et al., 2008). AEA
also markedly suppresses human epidermal KC proliferation and induces apoptosis via
CB1 in vitro and in situ (Toth et al., 2011). This suggests that the ECS could become a useful
therapeutic target in the management of chronic hyperproliferative human skin diseases,
such as psoriasis (Toth et al., 2011).
However, it remains unclear whether and how CB1-mediated signaling impacts on
human KC differentiation, namely on the expression of hyperproliferation-associated
keratins. Psoriasis is characterized by the upregulation of keratins K6 and K16 expression
within lesional epidermis (Korver et al., 2006; Mommers et al., 2000). This pair of keratins
is also prominently up-regulated in the epidermis under wound healing conditions in men
and mice (Moll, Divo & Langbein, 2008; Paladini et al., 1996; Rotty & Coulombe, 2012)
and is constitutively expressed in the outer root sheath KCs of human HFs (Langbein &
Schweizer, 2005; Moll, Divo & Langbein, 2008; Ramot et al., 2009). Psoriasis is a chronic
inflammatory, hyperproliferative dermatosis that, in addition to its anti-proliferative
properties (Telek et al., 2007; Van Dross et al., 2012), might also profit from the
well-recognized anti-inflammatory properties of CB1-mediated signaling (Sugawara et
al., 2012; Wilkinson & Williamson, 2007). Therefore, we have investigated whether CB1
stimulation modulates K6 and K16 expression in human skin. This question was made
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particularly interesting in view of the most recent discovery that, in murine skin, K6 is not
only a wound healing-associated keratin, but actively down-regulates KC migration during
wound repair (Rotty & Coulombe, 2012).
In order to answer this question, we used the CB1-specific agonist, arachidonoyl-
chloro-ethanolamide (ACEA) (Harvey et al., 2012), and checked its effect on K6 expression
in situ. This was done by utilizing full thickness human skin organ culture (Lu et al., 2007)
as a physiologically and clinically relevant model to study multiple aspects of human
skin biology under clinically relevant conditions in vitro (Bodo et al., 2010; Knuever et al.,
2012; Langan et al., 2010; Lu et al., 2007; Sugawara et al., 2012). In order to confirm the
CB1-specificity of the observed effects of ACEA, we also used the CB1-specific antagonist,
AM251 (Chanda et al., 2011).
K16 serves as the type I keratin partner of K6 in the formation of intermediate
filament heterodimers (Moll, Divo & Langbein, 2008). It is also involved in epidermal
barrier function (Grzanka et al., 2012; Thakoersing et al., 2012), and is up-regulated in
hyperprolifeative conditions of the skin such as psoriasis (Iizuka et al., 2004) and atopic
dermatitis (Grzanka et al., 2012). Therefore, we also examined the effects of ACEA on K16
expression.
HaCaT cells are a highly proliferating human KC line known to overexpress K6
(Ryle et al., 1989). Since HaCaT KCs share some other characteristics with psoriatic
KCs and are often employed as surrogate “psoriatic” KCs (Balato et al., 2012; Farkas
et al., 2001; George et al., 2010; Kim et al., 2011; Ronpirin & Tencomnao, 2012; Saelee,
Thongrakard & Tencomnao, 2011), we also tested whether and how ACEA modulated
K6 expression in these cells in vitro. In order to delineate whether any such effects
on keratin expression resulted only indirectly from a possible down-regulation of KC
proliferation by CB1 stimulation (Toth et al., 2011), double-labeling and quantitative
immunohistomorphometry for both K6 and Ki-67 was performed. Finally, to investigate
whether K6-expressing human KCs co-express CB1, double-immunolabeling for both
antigens was employed.
MATERIALS AND METHODS
Human skin organ culture
Isolated human skin samples obtained from elective plastic surgery procedures (32 pieces
of skin fragments obtained by 4 mm punch biopsies from 4 individuals; 3 females and
a male aged 26–74, average: 56.5; 3 skin samples were taken from the scalp and one
was taken from the hip) were maintained in supplemented serum-free William’s E
medium as previously reported (Bodo et al., 2010; Knuever et al., 2012; Lu et al., 2007;
Poeggeler et al., 2010). Human tissue collection and handling was performed according
to Helsinki guidelines, after institutional review board ethics approval (University of
Luebeck) and informed patient consent.
Skin samples were first incubated overnight to adapt to culture conditions after
which the medium was replaced and vehicle or test substances were added. For human
skin organ culture, skin samples were treated with ACEA (Sigma-Aldrich, Taufkirchen,
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Germany, 30 µM) or AM251 (Sigma-Aldrich, 1 µM), or the combination of them for
1-day after the overnight incubation (Sugawara et al., 2012). Following culturing for
the time indicated, skin samples were cryoembedded and prepared for histology, im-
munohistochemistry/immunofluorescence and quantitative immunohistomorphometry
(Ramot et al., 2010; Ramot et al., 2011; Sugawara et al., 2012). Each evaluation was
performed on 2–4 sections of 2 skin fragments per each treatment group from 2–4
individuals.
Cell culture
Human immortalized HaCaT KCs (Boukamp et al., 1988) were cultured in DMEM
(Sigma-Aldrich) supplemented with 10% fetal bovine serum (Invitrogen, Paisley, UK) and
antibiotics (PAA Laboratories, Pasching, Austria). For qRT-PCR, the cells were cultured
with ACEA (1 µM) for 8 h.
qRT-PCR
qRT-PCR was performed on an ABI Prism 7000 sequence detection system (Applied
Biosystems/Life Technologies, Foster City, CA, USA) using the 5’ nuclease assay as detailed
in our previous reports (Toth et al., 2011; Toth et al., 2009). Total RNA was isolated from
HaCaT keratinocytes using TRIreagent (Applied Biosystems/Life Technologies, Foster City,
CA, USA) and digested with recombinant RNase-free DNase-1 (Applied Biosystems)
according to the manufacturer’s protocol. After isolation, one µg of total RNA was
reverse-transcribed into cDNA by using High Capacity cDNA kit (Applied Biosystems)
following the manufacturer’s protocol. PCR amplification was performed by using specific
TaqMan primer and probes (Applied Biosystems, assay ID: Hs01699178 g1 for human
K6A). As internal housekeeping gene control, transcripts of cyclophillin A (PPIA) were
determined (Assay ID: Hs99999904 for human PPIA). The amount of the K6A transcripts
was normalized to the control gene using the1CTmethod.
Immunohistochemistry
For the detection of K6 in organ cultured human skin as well as cultured HaCaT KCs,
indirect immunofluorescence staining was performed using mouse anti-human K6
antibody (Progen, Ks6.KA12) at 1:10 dilution as a primary antibody and rhodamine
conjugated goat anti-mouse IgG (Jackson Immunoresearch Laboratories, West Grove, PA)
at 1:200 dilution in phosphate-buffered saline (PBS) as a secondary antibody.
To study the proliferation of epidermal KCs, double-immunostaining for K6 and Ki-67
was performed. Briefly, after the staining for K6 with FITC conjugated goat anti-mouse
IgG (Jackson Immunoresearch Laboratories) as a secondary antibody, sections were
incubated overnight at 4 ◦C with a mouse anti-human Ki-67 antibody (DAKO, Hamburg,
Germany) at 1:20 in PBS. Sections were then washed with PBS, followed by incubation
with rhodamine conjugated goat anti-mouse IgG (Jackson Immunoresearch Laboratories)
(1:200 in PBS, 45 min) at room temperature.
To investigate the localization of CB1 and K6, double immunostaining was performed.
For CB1 immunostaining, the highly sensitive tyramide signal amplification (TSA)
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technique (Perkin Elmer, Boston, MA) was applied. Cryosections were incubated
overnight at 4 ◦C with rabbit anti-CB1 (Santa Cruz, CA, USA) at 1:400 diluted in TNB
(Tris, NaOH, Blocking reagent, TSA kit; Perkin-Elmer). Thereafter, the samples were
labeled with goat biotinylated antibody against rabbit IgG (Jackson Immunoresearch
Laboratories) at 1:200 in TNB for 45 min at room temperature. Sections were then
stained with streptavidin-conjugated horseradish peroxidase (1:100, 30 min, TSA kit)
and were finally incubated with rhodamine conjugated tyramide (1:50, TSA kit). The TSA
method was applied according to the manufacturer’s protocol. For the second primary
labeling, mouse anti-human K6 antibody (Progen) was applied at 1:20 in PBS, overnight
at 4 ◦C. After the wash with PBS, the sections were incubated with FITC conjugated goat
anti-mouse IgG (Jackson Immunoresearch Laboratories) (1:200 in PBS, 45 min) at room
temperature.
For K16 antigen detection, we used the LSAB (DCS, Germany) detection method
(Ramot et al., 2009) using the K16-gp as primary antibody (guinea-pig, PROGEN,
Heidelberg, Germany, dilution 1:1000, GP-CK16), and biotinylated goat anti-guinea
pig as secondary antibody (Vector Laboratories, Burlingame, CA, USA, dilution 1:200).
HistoGreen (Linaris, Wertheim-Bettingen, Germany) was used as peroxidase substrate.
For all immunostainings, the respective primary antibodies were omitted as negative
controls, and morphological criteria and reproduction of the previously published
intracutaneous expression patterns of the examined antigens were used as internal
positive and negative controls (Moll, Divo & Langbein, 2008). For all experiments, control
and treated sections were stained (and later evaluated) on the same day by the same
investigator. To avoid staining biases, we calculated the relative staining intensity (arbitrary
intensity; 1 as control group) among treatment groups per each individual and then pooled
data from all of the experiments.
High magnification images of K6/Ki67 double immunofluorescence and K6 im-
munofluorescence on HaCaT cells were taken by laser scanning confocal microscopy
(Fluoview 300, Olympus Tokyo, Japan) running Fluoview 2.1 software (Olympus).
The staining intensity of K6 and K16 in defined reference areas was assessed by
quantitative immunohistomorphometry using the ImageJ software (NIH: National
Institutes of Health, Bethesda, MD) (Bodo et al., 2010; Ramot et al., 2010; Ramot et al.,
2011). For epidermal evaluation, staining intensity was evaluated in the suprabasal cells,
and for HaCaT cells, staining intensity was measured in the colonies formed. For K6
immunofluorescence intensity, skin sections from 4 different individuals were used, while
K16 immunofluorescence intensity and %Ki67 were evaluated in skin sections from 2
patients. 4–6 sections per one individual (2 sections per investigated skin fragment) were
used for each evaluation. Each section was evaluated in two/three different non-adjacent
microscopic fields (×200), and the mean intensity was measured, and considered as a
value. Each treatment group was compared to the control group (average value), and
relative change in expression was calculated. Highly comparable results were obtained
from different sections from different individuals.
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STATISTICAL ANALYSIS
Significance of difference between two groups was evaluated using Student’s t-test for
unpaired samples. For multiple comparisons, one-way analysis of variance (ANOVA)
was used, followed by Bonferroni’s multiple comparison test, using Prism 5.0 software
(GraphPad Prism Program, GraphPad, San Diego, CA). p values<0.05 were regarded as
significant. All data in the figures are expressed as mean+ SEM. *p < 0.05, **p < 0.01,
***p< 0.001 for the indicated comparisons.
RESULTS AND DISCUSSION
The CB1-selective agonist, ACEA, down-regulates K6 protein
expression in situ
First, we asked whether the CB1-specific synthetic agonist ACEA (Pertwee et al., 2010;
Sugawara et al., 2012) can modulate the expression of keratin K6 in human skin. K6
staining intensity within the epidermis of full-thickness human skin that had been
organ-cultured for 24 h under serum-free conditions in the presence of ACEA (30 µM)
or vehicle alone was assessed by quantitative immunohistomorphometry. This showed that
K6 immunoreactivity (IR) was significantly reduced after ACEA treatment, compared to
the vehicle control group (Figs. 1A and 1B).
This down-regulation was abrogated in part by the co-administration with the
CB1-specific antagonist, AM251 (Pertwee et al., 2010; Sugawara et al., 2012) (Figs. 1A
and 1B). Therefore, intraepidermal K6 protein expression in normal human skin in situ is
down-regulated in a CB1-specific manner.
ACEA also down-regulates K16 protein expression in situ
Since K16 is the type I keratin partner of K6 in KCs and is thought to stabilize this keratin
protein as a cytoskeletal heteropolymeric intermediate filament (Ramot et al., 2009), we
next analyzed K16 IR in the epidermis of organ cultured human skin samples treated with
ACEA. In line with the K6 protein expression, K16 IR was also significantly down-regulated
by ACEA in situ (Figs. 1C and 1D).
CB1-mediated signaling also regulates K6 expression in cultured,
hyperproliferative human keratinocytes
In order to check whether the observed CB1-mediated effects on K6 regulation within
intact human skin epithelium depend on intact epithelial-mesenchymal interactions
between epidermis and dermis, or are likely to reflect a direct impact of CB1 ligands on
epidermal keratinocytes, we next investigated K6 expression in cultured human HaCaT
KCs. This transformed human KC line is well-appreciated to constitutively express K6
and to be hyperproliferative (just like human wounded and psoriatic KC) (Balato et al.,
2012; Farkas et al., 2001; George et al., 2010; Kim et al., 2011; Ronpirin & Tencomnao,
2012; Ryle et al., 1989; Saelee, Thongrakard & Tencomnao, 2011). K6 is expressed in hyper-
proliferative cells (Weiss, Eichner & Sun, 1984) and both K6 expression and basal layer
epidermal KC proliferation are increased in psoriasis lesions (Donetti et al., 2012; Griffiths
& Barker, 2007; Korver et al., 2006; Litvinov et al., 2011; Mommers et al., 2000). HaCaT cells
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Figure 1 The CB1 specific agonist, ACEA significantly inhibits K6 and K16 expression in situ. (A) Rep-
resentative images of K6 immunofluorescence with organ cultured human skin treated with
ACEA/AM251 (1-day). (B) Statistical analysis of K6 immunofluorescence intensity in organ cultured
human skin (quantitative immunohistomorphemtry, ImageJ); stimulation with ACEA (30 µM), AM251
(1 µM) or both for 1-day. n = 9–22 skin sections/group. (C) Representative images of K16 immuno-
histochemistry with organ cultured human skin samples with ACEA (1-day). (D) Quantitative K16
immunohistomorphometry within the epidermis of organ-cultured human skin samples after 1-day
of stimulation with ACEA (30 µM). n = 4 skin sections/group. Data are expressed as mean + SEM.
*p< 0.05, **p< 0.01.
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Figure 2 The CB1 specific agonist, ACEA significantly inhibits K6 expression in cultured HaCaT
cells. (A) Representative images of K6 immunofluorescence of cultured HaCaT KCs with ACEA (1 µM),
AM251 (100 nM) or both for 1-day. (B) Statistical analysis of K6 immunofluorescence intensity of
cultured HaCaT cells. n= 6 colonies/group (C) Statistical analysis of K6 gene expression in HaCaT cells
treated with vehicle control or ACEA (1 µM) for 8 h. Data are expressed as mean + SEM. *p < 0.05;
**p< 0.01; ***p< 0.001.
are known to express functional CB1 and CB2 (Leonti et al., 2010; Maccarrone et al., 2003;
Paradisi et al., 2008), and this had been confirmed previously by our group, both on the
gene (RT-PCR analysis) and protein levels (immunocytochemistry and western blotting
techniques) (Toth et al., 2011). Thus, being a direct target of CB1-mediated signaling,
this makes these KCs not only an instructive cell culture tool for evaluating the direct,
dermis-independent role of CB1-mediated signaling in the regulation of keratin expression
in human KCs, but may also provide first indications as to how the observed K6 expression
could relate to wound healing and/or psoriasis.
In accordance with our human skin organ culture results, ACEA (1 µM) significantly
down-regulated K6 staining intensity of HaCaT cells in vitro (Figs. 2A and 2B). This was
abrogated by the co-administration of the selective CB1 antagonist, AM251 (100 nM)
(Figs. 2A and 2B). Unexpectedly, though, AM251 alone had a partial inhibitory effect on
K6 expression, although not significant. This may be related to the fact that AM251 is an
inverse agonist (Dono & Currie, 2012; Fiori et al., 2011), and invites further study. The
inhibitory effect of ACEA on K6 protein expression was further confirmed by quantitative
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Figure 3 The CB1 specific agonist, ACEA significantly decreases human epidermal keratinocyte pro-
liferation in situ. (A) Representative images of K6 (green) and Ki67 (red) double-immunofluorescence
with organ cultured human skin treated with ACEA/AM251 (1-day). (B) Quantitative analysis of the
percentage of Ki67+ KCs within organ cultured human epidermis. *p < 0.05; ***p < 0.001. n = 5–12
skin sections/group.
RT-PCR (Fig. 2C). Therefore, while HaCaT cells may exhibit relatively low CB expression
levels, at least under our assay conditions, they showed a vigorous response to CB ligands.
The CB1 specific agonist, ACEA significantly decreases human
epidermal keratinocyte proliferation in situ
However, the observed effects of CB1-mediated signaling on epidermal K6 expression
could simply reflect the appreciated anti-proliferative effects of CB1 agonists (Casanova et
al., 2003; Hermanson & Marnett, 2011; Toth et al., 2011). Moreover, K6 is overexpressed
in hyper-proliferative and wounded KCs (Weiss, Eichner & Sun, 1984), and both K6
expression and basal KC proliferation are increased in psoriatic epidermal lesions (Donetti
et al., 2012; Griffiths & Barker, 2007; Korver et al., 2006; Litvinov et al., 2011; Mommers
et al., 2000; Navarro, Casatorres & Jorcano, 1995). Therefore, we next assessed whether
CB1 stimulation by CB1 specific agonist, ACEA, could affect human KC proliferation
in situ.
Just as we had seen before with the non-selective endocannabinoid, AEA (Toth et al.,
2011), the CB1-specific synthetic agonist, ACEA indeed significantly decreased human epi-
dermal KC proliferation in situ. This effect was abrogated by the CB1-specific antagonist,
AM251 (assessed by quantitative Ki-67 immunomorphometry, Figs. 3A and 3B).
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The CB1 specific agonist, ACEA, significantly decreases K6 ex-
pression in suprabasal cells in a proliferation-independent manner
Therefore, it needed to be dissected whether or not CB1 also reduces K6 expression in a
proliferation-independent manner. This was done by selectively assessing K6 expression in
non-proliferative (i.e. Ki-67-negative) epidermal KCs in situ. We found that K6 IR within
non-proliferative epidermis was also reduced by ACEA (Figs. 4A and 4B). Furthermore,
K6-expressing cells in the epidermis co-expressed CB1 in situ (Fig. 4C), suggesting a
direct effect of CB1-agnosits on K6-expressing human epidermal KCs in situ. Thus, CB1
stimulation may affect K6 expression both, by reducing KC proliferation and by down-
regulating K6 expression directly via CB1 in a proliferation-independent manner.
Here we provide the first evidence that CB1-mediated signaling directly regulates
K6/16 expression within normal human skin. Specifically, we show that CB1 stimulation
down-regulates expression of the hyper-proliferation-associated human keratins K6 in
vitro and in situ, and inhibits human epidermal KC proliferation in situ.
The effect of CB-mediated signaling in human KC biology remains to be fully explored.
As we have also observed in isolated human skin (Fig. 4C), CB1 protein expression is
detected mainly above the basal layer of the epidermis (Stander et al., 2005), i.e. above the
compartment where KC proliferation normally occurs most prominently. Wilkinson and
Williamson reported that the non-selective CB agonist HU210 inhibited KC proliferation.
However, this could not be blocked by either CB1 or CB2 antagonists, suggesting
that cannabinoids may also inhibit human KC proliferation through a non-CB1/CB2
mechanism (Wilkinson & Williamson, 2007). Nevertheless, it has been previously shown
that AEA, which can interact with CB1 on human KC (Biro et al., 2009), inhibited human
KC proliferation in situ and in vitro (Toth et al., 2011).
Therefore, it was important to clarify whether specific CB1 stimulation inhibits human
epidermal KC proliferation in situ. By using CB1-specific agonists and antagonists we
clearly demonstrate that exclusive CB1 stimulation inhibited KC proliferation. Thus, CB1
is an important key regulator of human KC proliferation. Given the role of epidermal
hyperproliferation in the pathobiology of psoriasis (Donetti et al., 2012; Griffiths & Barker,
2007; Korver et al., 2006; Litvinov et al., 2011; Mommers et al., 2000; Navarro, Casatorres &
Jorcano, 1995), cannabimimetic agents that activate CB1, therefore, deserve consideration
as a novel pharmacological strategy for treating psoriasis.
Furthermore, increased numbers of activated mast cells are often observed in and
around lesional psoriatic skin, and increasing evidence suggests that mast cells are
functionally important key immunocytes in the pathogenesis of psoriasis (Carvalho,
Nilsson & Harvima, 2010; Namazi, 2005; Radosa et al., 2011; Suttle et al., 2012; Toruniowa
& Jablonska, 1988). Recently, we have shown that CB1 activation limits excessive mast cell
activity and even inhibits mast cell maturation of resident, intracutaneous progenitors
(Sugawara et al., 2012). Therefore, besides their anti-proliferative effects on human
epidermal KCs, the anti-inflammatory (Richardson, Kilo & Hargreaves, 1998) and mast
cell-inhibitory properties of CB1 agonists in human skin (Sugawara et al., 2012) make
them a particularly attractive class of agents in future psoriasis management.
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Figure 4 The CB1 specific agonist, ACEA, significantly decreases K6 expression in suprabasal cells
in a proliferation-independent manner. (A) Representative images of K6 (green) and Ki-67 (red)
double immunofluorescence. Dotted rectangles indicate the reference area for quantitative immunohis-
tomorphometry of K6 fluorescence intensity. (B) Quantitative analysis of K6 fluorescence intensity in
non-proliferating (i.e. Ki67-negative) cells within human epidermis in situ. Data are expressed as mean+
SEM. *p< 0.05. n= 5–7 skin sections/group. (C) K6 (green) and CB1 (red) double-immunofluorescence
study. Yellow arrows denote double-positive KCs.
It should be noted, that the constitutive level of K6 expression in organ-cultured human
skin fragments is considerably higher than normal scalp skin in vivo. Presumably, this
occurs as a response to tissue dissection and organ culture, which is well-known to elicit
an immediate wound healing response in the epithelium. The latter rapidly starts to
migrate over the wound edge in an attempt to enwrap the exposed skin mesenchyme
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(epiboly phenomenon Stenn, 1981; Brown et al., 1991). This constitutive up-regulation
of K6 in organ-cultured normal human skin may greatly heighten the sensitivity to K6
expression-modulatory compounds, such as CB ligands, thus making human skin organ
culture a particularly sensitive and instructive tool for clinically relevant keratin research.
At the same time, however, caution is advised in extrapolating from these observation
made in what essentially reflects a wound healing milieu to healthy, unmanipulated human
skin in vivo.
The current findings invite the speculation that the therapeutic down-modulation of
K6 and/or K16 expression by CB1 agonists and other cannabimimetics might become
exploitable for the management of other dermatoses besides psoriasis, for example
pachyonychia congenita (Hickerson et al., 2011; Zhao et al., 2011) and acne (Biro et al.,
2009), and could be used to modulate KC migration-dependent reepithelialization in
wound healing, similar to related findings in periodontal and intestinal wound repair
(Kozono et al., 2010; Wright et al., 2005).
CONCLUSION
Our results suggest that cannabinoids and their receptors constitute a novel, clinically
relevant control element of human K6 and K16 expression. Therefore, cannabimimetic
agents might be relevant for the treatment of several skin conditions related to aberrant
K6/K16 expression, such as psoriasis and wound healing. In addition, skin organ culture
is shown to be a clinically and physiologically relevant model system for investigating the
effect of CB1 specific agonists/antagonists on human skin.
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AEA anandamide
CB1 cannabinoid receptor 1
ECS endocannabinoid system
HF hair follicle
KC keratinocyte
ACKNOWLEDGEMENTS
The authors thank Motoko Sugawara for her excellent technical assistance, and Dr. Stephan
Tiede for professional advice. The generous professional support of Prof. Masamitsu
Ishii and Prof. Hiromi Kobayashi, Osaka, for this work is also gratefully appreciated.
Dr. Wolfgang Funk is gratefully acknowledged for harvesting human skin samples for
the organ culture.
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
This study was supported in part by the Daniel Turnberg United Kingdom/Middle East
Travel Fellowship Scheme, administered by the Academy of Medical Sciences to YR; a
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 12/18
faculty grant from Osaka City University to KS; a “Lendu¨let” grant of the Hungarian
Academy of Sciences to TB; and a faculty grant from the University of Luebeck to RP. The
funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Grant Disclosures
The following grant information was disclosed by the authors:
Daniel Turnberg United Kingdom/Middle East Travel Fellowship Scheme.
Osaka City University.
“Lendu¨let” grant of the Hungarian Academy of Sciences.
University of Luebeck.
Competing Interests
Ralf Paus is an Academic Editor for PeerJ.
Author Contributions
• Yuval Ramot and Koji Sugawara conceived and designed the experiments, performed
the experiments, analyzed the data, wrote the paper.
• No´ra Za´ka´ny and Bala´zs I. To´th performed some of the experiments, and contributed
and analyzed qRT-PCR data.
• Tama´s Bı´ro´ contributed and analyzed qRT-PCR data and edited the paper.
• Ralf Paus conceived, designed, and supervised the experiments, and wrote the paper.
Human Ethics
The following information was supplied relating to ethical approvals (i.e. approving body
and any reference numbers):
Institutional review board ethics committee of the University of Luebeck, reference
number 06-109.
REFERENCES
Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, Zimmer A, Distler O, Schett G,
Distler JH. 2009. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental
dermal fibrosis. Arthritis and Rheumatism 60:1129–1136 DOI ./art..
Balato A, Lembo S, Mattii M, Schiattarella M, Marino R, De Paulis A, Balato N, Ayala F.
2012. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory
cytokines via keratinocyte and mast cell activation. Experimental Dermatology 21:892–894
DOI ./exd..
Biro T, Toth BI, Hasko G, Paus R, Pacher P. 2009. The endocannabinoid system of the skin in
health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological
Sciences 30:411–420 DOI ./j.tips....
Bodo E, Kany B, Gaspar E, Knuver J, Kromminga A, Ramot Y, Biro T, Tiede S, van Beek N,
Poeggeler B, Meyer KC, Wenzel BE, Paus R. 2010. Thyroid-stimulating hormone, a
novel, locally produced modulator of human epidermal functions, is regulated by
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 13/18
thyrotropin-releasing hormone and thyroid hormones. Endocrinology 151:1633–1642
DOI ./en.-.
Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. 1988.
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell
line. Journal of Cell Biology 106:761–771 DOI ./jcb....
Brown C, Stenn KS, Falk RJ, Woodley DT, O’Keefe EJ. 1991. Vitronectin: effects on keratinocyte
motility and inhibition of collagen-induced motility. Journal of Investigative Dermatology
96:724–728 DOI ./-.ep.
Carvalho RF, Nilsson G, Harvima IT. 2010. Increased mast cell expression of PAR-2 in skin
inflammatory diseases and release of IL-8 upon PAR-2 activation. Experimental Dermatology
19:117–122 DOI ./j.-...x.
Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ,
Huffman JW, Jorcano JL, Guzman M. 2003. Inhibition of skin tumor growth and angiogenesis
in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation 111:43–50
DOI ./JCI.
Chanda D, Kim DK, Li T, Kim YH, Koo SH, Lee CH, Chiang JY, Choi HS. 2011. Cannabinoid
receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of
endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding
protein H (CREBH) in primary hepatocytes. Journal of Biological Chemistry 286:27971–27979
DOI ./jbc.M..
Czifra G, Szollosi AG, Toth BI, Demaude J, Bouez C, Breton L, Biro T. 2012. Endocannabinoids
regulate growth and survival of human eccrine sweat gland-derived epithelial cells. Journal of
Investigative Dermatology 132:1967–1976 DOI ./jid...
Dobrosi N, Toth BI, Nagy G, Dozsa A, Geczy T, Nagy L, Zouboulis CC, Paus R, Kovacs L,
Biro T. 2008. Endocannabinoids enhance lipid synthesis and apoptosis of human
sebocytes via cannabinoid receptor-2-mediated signaling. FASEB Journal 22:3685–3695
DOI ./fj.-.
Donetti E, Gualerzi A, Ricceri F, Pescitelli L, Bedoni M, Prignano F. 2012. Etanercept restores
a differentiated keratinocyte phenotype in psoriatic human skin: a morphological study.
Experimental Dermatology 21:549–551 DOI ./j.-...x.
Dono LM, Currie PJ. 2012. The cannabinoid receptor CB(1) inverse agonist AM251 potentiates
the anxiogenic activity of urocortin I in the basolateral amygdala. Neuropharmacology
62:192–199 DOI ./j.neuropharm....
Farkas A, Kemeny L, Szony BJ, Bata-Csorgo Z, Pivarcsi A, Kiss M, Szell M, Koreck A, Dobozy A.
2001. Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line
HaCaT. Inflammation Research 50:44–49 DOI ./s.
Fiori JL, Sanghvi M, O’Connell MP, Krzysik-Walker SM, Moaddel R, Bernier M. 2011. The
cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor
and its ligands via destabilization of oestrogen-related receptor alpha protein. British Journal of
Pharmacology 164:1026–1040 DOI ./j.-...x.
George SE, Anderson RJ, Cunningham A, Donaldson M, Groundwater PW. 2010. Evaluation
of a range of anti-proliferative assays for the preclinical screening of anti-psoriatic drugs: a
comparison of colorimetric and fluorimetric assays with the thymidine incorporation assay.
Assay and Drug Development Technologies 8:389–400 DOI ./adt...
Griffiths CE, Barker JN. 2007. Pathogenesis and clinical features of psoriasis. Lancet 370:263–271
DOI ./S-()-.
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 14/18
Grzanka A, Zebracka-Gala J, Rachowska R, Bozek A, Kowalska M, Jarzab J. 2012. The effect
of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic der-
matitis skin lesions. Experimental Dermatology 21:184–188 DOI ./j.-...x.
Harvey BS, Ohlsson KS, Maag JL, Musgrave IF, Smid SD. 2012. Contrasting protective effects
of cannabinoids against oxidative stress and amyloid-beta evoked neurotoxicity in vitro.
Neurotoxicology 33:138–146 DOI ./j.neuro....
Hermanson DJ, Marnett LJ. 2011. Cannabinoids, endocannabinoids, and cancer. Cancer and
Metastasis Reviews 30:599–612 DOI ./s---.
Hickerson RP, Leachman SA, Pho LN, Gonzalez-Gonzalez E, Smith FJ, McLean WH,
Contag CH, Leake D, Milstone LM, Kaspar RL. 2011. Development of quantitative molecular
clinical end points for siRNA clinical trials. Journal of Investigative Dermatology 131:1029–1036
DOI ./jid...
Iizuka H, Takahashi H, Honma M, Ishida-Yamamoto A. 2004. Unique keratinization process in
psoriasis: late differentiation markers are abolished because of the premature cell death. Journal
of Dermatology 31:271–276.
Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R,
Schlicker E, Cravatt B, Mechoulam R, Buettner R, Werner S, Di Marzo V, Tuting T,
Zimmer A. 2007. Attenuation of allergic contact dermatitis through the endocannabinoid
system. Science 316:1494–1497 DOI ./science..
Khasabova IA, Khasabov S, Paz J, Harding-Rose C, Simone DA, Seybold VS. 2012. Cannabinoid
type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. Journal of
Neuroscience 32:7091–7101 DOI ./JNEUROSCI.-..
Kim TG, Byamba D, Wu WH, Lee MG. 2011. Statins inhibit chemotactic interaction between
CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment. Experimental Dermatology
20:855–857 DOI ./j.-...x.
Klein TW. 2005. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews
Immunology 5:400–411 DOI ./nri.
Knuever J, Poeggeler B, Gaspar E, Klinger M, Hellwig-Burgel T, Hardenbicker C, Toth BI,
Biro T, Paus R. 2012. Thyrotropin-releasing hormone controls mitochondrial biology
in human epidermis. Journal of Clinical Endocrinology and Metabolism 97:978–986
DOI ./jc.-.
Korver JE, van Duijnhoven MW, Pasch MC, van Erp PE, van de Kerkhof PC. 2006. Assessment
of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional
skin of spreading psoriasis. British Journal of Dermatology 155:688–694 DOI ./j.-
...x.
Kozono S, Matsuyama T, Biwasa KK, Kawahara K, Nakajima Y, Yoshimoto T, Yonamine Y,
Kadomatsu H, Tancharoen S, Hashiguchi T, Noguchi K, Maruyama I. 2010. Involvement
of the endocannabinoid system in periodontal healing. Biochemical and Biophysical Research
Communications 394:928–933 DOI ./j.bbrc....
Kupczyk P, Reich A, Szepietowski JC. 2009. Cannabinoid system in the skin – a possible
target for future therapies in dermatology. Experimental Dermatology 18:669–679
DOI ./j.-...x.
Langan EA, Ramot Y, Hanning A, Poeggeler B, Biro T, Gaspar E, Funk W, Griffiths CE, Paus R.
2010. Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and
prolactin receptor expression in female human skin and hair follicles in vitro. British Journal of
Dermatology 162:1127–1131 DOI ./j.-...x.
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 15/18
Langbein L, Schweizer J. 2005. Keratins of the human hair follicle. International Review of Cytology
243:1–78 DOI ./S-()-.
Leonti M, Casu L, Raduner S, Cottiglia F, Floris C, Altmann KH, Gertsch J. 2010. Falcarinol
is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin.
Biochemical Pharmacology 79:1815–1826 DOI ./j.bcp....
Litvinov IV, Bizet AA, Binamer Y, Jones DA, Sasseville D, Philip A. 2011. CD109 release from
the cell surface in human keratinocytes regulates TGF-beta receptor expression, TGF-beta
signalling and STAT3 activation: relevance to psoriasis. Experimental Dermatology 20:627–632
DOI ./j.-...x.
Lu Z, Hasse S, Bodo E, Rose C, Funk W, Paus R. 2007. Towards the development of a simplified
long-term organ culture method for human scalp skin and its appendages under serum-free
conditions. Experimental Dermatology 16:37–44 DOI ./j.-...x.
Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, Finazzi-Agro A. 2003.
The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits
epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C,
activation protein-1, and transglutaminase. Journal of Biological Chemistry 278:33896–33903
DOI ./jbc.M.
Moll R, Divo M, Langbein L. 2008. The human keratins: biology and pathology. Histochemistry
and Cell Biology 129:705–733 DOI ./s---.
Mommers JM, van Rossum MM, van Erp PE, van De Kerkhof PC. 2000. Changes in keratin 6 and
keratin 10 (co-)expression in lesional and symptomless skin of spreading psoriasis. Dermatology
201:15–20 DOI ./.
Namazi MR. 2005. Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic
ammunition. Journal of the European Academy of Dermatology and Venereology 19:319–322
DOI ./j.-...x.
Navarro JM, Casatorres J, Jorcano JL. 1995. Elements controlling the expression and induction
of the skin hyperproliferation-associated keratin K6. Journal of Biological Chemistry
270:21362–21367 DOI ./jbc....
Paladini RD, Takahashi K, Bravo NS, Coulombe PA. 1996. Onset of re-epithelialization after
skin injury correlates with a reorganization of keratin filaments in wound edge keratinocytes:
defining a potential role for keratin 16. Journal of Cell Biology 132:381–397
DOI ./jcb....
Paradisi A, Pasquariello N, Barcaroli D, Maccarrone M. 2008. Anandamide regulates
keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent
manner. Journal of Biological Chemistry 283:6005–6012 DOI ./jbc.M.
Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ,
Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. 2010. International Union of Basic
and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1)
and CB(2). Pharmacological Reviews 62:588–631 DOI ./pr...
Poeggeler B, Knuever J, Gaspar E, Biro T, Klinger M, Bodo E, Wiesner RJ, Wenzel BE,
Paus R. 2010. Thyrotropin powers human mitochondria. FASEB Journal 24:1525–1531
DOI ./fj.-.
Pucci M, Pasquariello N, Battista N, Di Tommaso M, Rapino C, Fezza F, Zuccolo M,
Jourdain R, Finazzi Agro A, Breton L, Maccarrone M. 2012. Endocannabinoids stimulate
human melanogenesis via type-1 cannabinoid receptor. Journal of Biological Chemistry
287:15466–15478 DOI ./jbc.M..
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 16/18
Radosa J, Dyck W, Goerdt S, Kurzen H. 2011. The cholinergic system in guttate psoriasis
with special reference to mast cells. Experimental Dermatology 20:677–679 DOI ./j.-
...x.
Ramot Y, Biro T, Tiede S, Toth BI, Langan EA, Sugawara K, Foitzik K, Ingber A, Goffin V,
Langbein L, Paus R. 2010. Prolactin – a novel neuroendocrine regulator of human keratin
expression in situ. FASEB Journal 24:1768–1779 DOI ./fj.-.
Ramot Y, Gaspar E, Dendorfer A, Langbein L, Paus R. 2009. The ‘melanocyte-keratin’ mystery
revisited: neither normal human epidermal nor hair follicle melanocytes express keratin
16 or keratin 6 in situ. British Journal of Dermatology 161:933–938 DOI ./j.-
...x.
Ramot Y, Tiede S, Biro T, Abu Bakar MH, Sugawara K, Philpott MP, Harrison W, Pietila M,
Paus R. 2011. Spermidine promotes human hair growth and is a novel modulator of human
epithelial stem cell functions. PLoS ONE 6:e22564 DOI ./journal.pone..
Richardson JD, Kilo S, Hargreaves KM. 1998. Cannabinoids reduce hyperalgesia and
inflammation via interaction with peripheral CB1 receptors. Pain 75:111–119
DOI ./S-()-.
Roelandt T, Heughebaert C, Bredif S, Giddelo C, Baudouin C, Msika P, Roseeuw D, Uchida Y,
Elias PM, Hachem JP. 2012. Cannabinoid receptors 1 and 2 oppositely regulate epidermal
permeability barrier status and differentiation. Experimental Dermatology 21:688–693
DOI ./j.-...x.
Ronpirin C, Tencomnao T. 2012. Effects of the antipsoriatic drug dithranol on E2A and
caspase-9 gene expression in vitro. Genetics and Molecular Research 11:412–420
DOI ./.February...
Rotty JD, Coulombe PA. 2012. A wound-induced keratin inhibits Src activity during keratinocyte
migration and tissue repair. Journal of Cell Biology 197:381–389 DOI ./jcb..
Ryle CM, Breitkreutz D, Stark HJ, Leigh IM, Steinert PM, Roop D, Fusenig NE. 1989.
Density-dependent modulation of synthesis of keratins 1 and 10 in the human keratinocyte
line HACAT and in ras-transfected tumorigenic clones. Differentiation 40:42–54
DOI ./j.-..tb.x.
Saelee C, Thongrakard V, Tencomnao T. 2011. Effects of Thai medicinal herb extracts with
anti-psoriatic activity on the expression on NF-kappaB signaling biomarkers in HaCaT
keratinocytes. Molecules 16:3908–3932 DOI ./molecules.
Stander S, Reinhardt HW, Luger TA. 2006. Topical cannabinoid agonists. An effective new
possibility for treating chronic pruritus. Hautarzt 57:801–807 DOI ./s---.
Stander S, Schmelz M, Metze D, Luger T, Rukwied R. 2005. Distribution of cannabinoid receptor
1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. Journal of
Dermatological Science 38:177–188 DOI ./j.jdermsci....
Stenn KS. 1981. Epibolin: a protein of human plasma that supports epithelial cell movement.
Proceedings of the National Academy of Sciences of the United States of America 78:6907–6911
DOI ./pnas....
Sugawara K, Biro T, Tsuruta D, Toth BI, Kromminga A, Zakany N, Zimmer A, Funk W,
Gibbs BF, Zimmer A, Paus R. 2012. Endocannabinoids limit excessive mast cell maturation
and activation in human skin. Journal of Allergy and Clinical Immunology 129:726–738
DOI ./j.jaci....
Suttle MM, Nilsson G, Snellman E, Harvima IT. 2012. Experimentally induced psoriatic lesion
associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 17/18
IL-33 and IL-6 receptor. Clinical and Experimental Immunology 169:311–319
DOI ./j.-...x.
Telek A, Biro T, Bodo E, Toth BI, Borbiro I, Kunos G, Paus R. 2007. Inhibition of human hair
follicle growth by endo- and exocannabinoids. FASEB Journal 21:3534–3541
DOI ./fj.-com.
Thakoersing VS, Danso MO, Mulder A, Gooris G, El Ghalbzouri A, Bouwstra JA. 2012. Nature
versus nurture: does human skin maintain its stratum corneum lipid properties in vitro?
Experimental Dermatology 21:865–870 DOI ./exd..
Toruniowa B, Jablonska S. 1988. Mast cells in the initial stages of psoriasis. Archives for dermato-
logical research. Archives of Dermatological Research 280:189–193 DOI ./BF.
Toth BI, Dobrosi N, Dajnoki A, Czifra G, Olah A, Szollosi AG, Juhasz I, Sugawara K, Paus R,
Biro T. 2011. Endocannabinoids modulate human epidermal keratinocyte proliferation and
survival via the sequential engagement of cannabinoid receptor-1 and transient receptor
potential vanilloid-1. Journal of Investigative Dermatology 131:1095–1104
DOI ./jid...
Toth BI, Geczy T, Griger Z, Dozsa A, Seltmann H, Kovacs L, Nagy L, Zouboulis CC, Paus R,
Biro T. 2009. Transient receptor potential vanilloid-1 signaling as a regulator of human sebocyte
biology. Journal of Investigative Dermatology 129:329–339 DOI ./jid...
Van Dross R, Soliman E, Jha S, Johnson T, Mukhopadhyay S. 2012. Receptor-dependent and
receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer
growth. Life Sciences DOI ./j.lfs....
Walker JM, Hohmann AG. 2005. Cannabinoid mechanisms of pain suppression. Handbook of
Experimental Pharmacology 168:509–554.
Weiss RA, Eichner R, Sun TT. 1984. Monoclonal antibody analysis of keratin expression in
epidermal diseases: a 48- and 56-kdalton keratin as molecular markers for hyperproliferative
keratinocytes. Journal of Cell Biology 98:1397–1406 DOI ./jcb....
Wilkinson JD, Williamson EM. 2007. Cannabinoids inhibit human keratinocyte proliferation
through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of
psoriasis. Journal of Dermatological Science 45:87–92 DOI ./j.jdermsci....
Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S. 2005. Differential
expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial
wound healing. Gastroenterology 129:437–453 DOI ./j.gastro....
Zhao Y, Gartner U, Smith FJ, McLean WH. 2011. Statins downregulate K6a promoter activity: a
possible therapeutic avenue for pachyonychia congenita. Journal of Investigative Dermatology
131:1045–1052 DOI ./jid...
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 18/18
